Pfizer has been forced to reduce staff numbers and implement billion-dollar cuts in its operating costs following the collapse in COVID-19 vaccine and treatment sales over the past 12 months.
The pharmaceutical giant is set to cut costs by $1 billion this year and at least $2.5 billion in 2024 as its annual revenue has almost halved from over $100 billion last year, with Coronavirus vaccine sales making up $56 million of that figure, to around $60 billion in 2023. There is yet to be a confirmed figure regarding job losses, however.
The company also anticipates sales of its vaccine and Paxlovid, another coronavirus medication, to be $12.5 billion, roughly $9 billion lower than initially forecasted.
“We remain proud that our scientific breakthroughs played a significant role in getting the global health crisis under control,” said Pfizer’s chief executive, Albert Bourla, following the announcement.
“As we gain additional clarity around vaccination and treatment rates for COVID, we will be better able to estimate the appropriate level of supply to meet demand,” Bourla added.
The fall in demand for COVID-19 vaccines has also forced countries to scrap hundreds of millions of doses.